
Northbaze Group Q2 2023 - Positive stance despite sales contraction

Redeye maintains a positive view of Northbaze, even in the face of a substantial sales contraction. While the company proactively addresses the reduced demand, the prevailing macroeconomic challenges continue to impact Northbaze's top and bottom-line performance. Despite a challenging quarter, Northbaze is steadfast in its pursuit of recuperating and upholding a 10% EBITDA margin in 2023. Our view on Northbaze remains unchanged, leading us to maintain our existing fair-value range and base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Northbaze Group Q2 2023 - Positive stance despite sales contraction](#)